Accelerate Diagnostics

The firm saw durable consumables revenue in Q3, added five contracted instruments in the quarter, and brought 22 new instruments live in the US.

Fujirebio Diagnostics got the nod for a chemiluminescent enzyme immunoassay to measure levels of CA 15-3 and manage patients diagnosed with breast cancer.

The additions improve the system's performance and expand its antimicrobial susceptibility testing menu for bloodstream infections.

The BioCheck chemiluminescence tests can process human serum samples in 30 minutes to detect IgG and IgM antibodies.

The chemiluminescent test targets antibodies against the virus' S1 protein which the firm believes is a particularly clinically relevant marker.

The firm also announced two new instruments that would diversify its product offerings.

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased.